Corona Vaccine : Likely or Unlikely?

Elias Hubbard
July 8, 2020

Medical experts expressed concern that the speedy trials would compromise patient safety and ethics. As for the trial launch, Moderna said it "made the call" to delay it, but the sources told Reuters that the biotech did not have enough staff to finish the trial protocols on time.

The vaccine, being jointly developed by India's Bharat Biotech and ICMR, is one of several candidates being tested globally to fight the coronavirus pandemic.

The University of Oxford and AstraZeneca's phase 3 clinical trial involves assessing how the vaccine works in a large number of people over the age of 18.

"The (July 2) letter could turn India into a laughing stock in the vaccine community". "It's not about getting there first but to be able to do it well and it is good that India has been able to come up with candidate vaccines, which is not a small achievement".

In its clarification, the ICMR said the July 2 letter had been meant to insulate the vaccine development process from "slow file movement". We only said that we envisage having a vaccine by 15 August and it is not a deadline.

The letter written by Bhargava, the report highlighted, has concerned many experts and triggered an outrage. "However, as a body of scientists-including many who are engaged in vaccine development-IASc strongly believes that the announced timeline is unfeasible.This timeline has raised unrealistic hope and expectations in the minds of our citizens", stated a statement issued by Partha P Mujumder of behalf of the Council and Fellowship of IASc. One prominent and early contribution was the discovery in 1922 of a compound to treat leishmaniasis or kala-azar, a parasite infection, by Upendranath Brahmachari, a Calcutta physician. Underlining India's role in global efforts to develop the vaccine, the ministry said, "In the past years, India has emerged as one of the significant vaccine manufacturing hubs". Bharat Biotech now produces the vaccine.

"Faced with the unprecedented nature of the COVID-19 pandemic, and the consequent dislocation of the normal life, all other vaccine candidates across the globe have been similarly fast-tracked", the agency claimed. "Now they are being considered in parallel", said the virologist, who too requested anonymity.

Meanwhile, the government of Sao Paulo state will start on July 20 testing for the vaccine by the Chinese biopharmaceutical company Sinovac on 9,000 volunteers.

No process in vaccine development trials would be skipped, said Ms. Swarup. There will be two vaccine dosage of three micrograms and six micrograms, and a placebo.

Elaborating on the lengthy process involved in vaccine development, he insisted that after spending many months and infusing a lot of funds, the uncertainty continues to linger. "ICMR's intentions may be good but the processes have been vitiated and the risk is it can derail the vaccine", he says. These conditions were laid out after the drug company presented data on "safety" and "immunogenicity" collected during pre-clinical trials conducted on rats, mice, and rabbits.

"The people of India deserve a safe and efficacious vaccine".

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER